KRAS
KRAS 詳細
| 英語名 | GTPase KRas | 市販薬剤の数 | 0 |
| 治験薬の数 | 40 | ターゲットの別称 | V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog，KRAS Proto-Oncogene， GTPase，K-Ras4B，KRAS1，KRAS2，V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog，Kirsten Rat Sarcoma Viral Oncogene Homolog，GTPase KRas，C-Ki-Ras，K-Ras 2，RASK2，Kirsten Rat Sarcoma Viral Proto-Oncogene，Cellular Transforming Proto-Oncogene，Cellular C-Ki-Ras2 Proto-Oncogene，Kras-Enoph1 Fusion Protein，Transforming Protein P21，PR310 C-K-Ras Oncogene，C-Kirsten-Ras Protein，Proto-Oncogene GTPase，K-Ras P21 Protein，KRAS-ENOPH Fusion，Oncogene KRAS2，EC 3.6.5.2，C-Ki-Ras2，'C-K-RAS，C-K-RAS，K-RAS2A，K-RAS2B，K-RAS4A，C-K-Ras，KI-RAS，Ki-Ras，K-Ras，CFC2，RALD，NS3，OES，NS |
| 研究＆開発段階 | Phase 2 Clinical | ||
| 英語名 | GTPase KRas |
| ターゲットの別称 | V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog，KRAS Proto-Oncogene， GTPase，K-Ras4B，KRAS1，KRAS2，V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog，Kirsten Rat Sarcoma Viral Oncogene Homolog，GTPase KRas，C-Ki-Ras，K-Ras 2，RASK2，Kirsten Rat Sarcoma Viral Proto-Oncogene，Cellular Transforming Proto-Oncogene，Cellular C-Ki-Ras2 Proto-Oncogene，Kras-Enoph1 Fusion Protein，Transforming Protein P21，PR310 C-K-Ras Oncogene，C-Kirsten-Ras Protein，Proto-Oncogene GTPase，K-Ras P21 Protein，KRAS-ENOPH Fusion，Oncogene KRAS2，EC 3.6.5.2，C-Ki-Ras2，'C-K-RAS，C-K-RAS，K-RAS2A，K-RAS2B，K-RAS4A，C-K-Ras，KI-RAS，Ki-Ras，K-Ras，CFC2，RALD，NS3，OES，NS |
| 市販薬剤の数 | 0 |
| 治験薬の数 | 40 |
| 研究＆開発段階 | Phase 2 Clinical |
KRAS 製品リスト
- 属性
Protein (13)
- 製品ライブラリ
オンライン (13)
- 種
Human (13)
- タグ
His Tag (10)His Tag & Avi Tag (3)
- マーカー
Unconjugated (13)
| 製品番号 | 種 | 発現システム | 製品説明 | タンパク質の構造 | 純度 | 特性 |
|---|---|---|---|---|---|---|
 Human | E. coli | Human KRAS (G12V) Protein, His Tag (active enzyme) |  |  | ||
| Human | E. coli | Human KRAS (2-185, G12C) Protein, His Tag (HPLC verified) (active enzyme) |  | | ||
| Human | E. coli | Human KRAS (2-185, G12D) Protein, His Tag (active enzyme) |  | | ||
| Human | E. coli | Human KRAS Protein, His Tag (active enzyme, HPLC verified) |  | | ||
| Human | E. coli | Human KRAS (G12S) Protein, His Tag (HPLC verified) (active enzyme) |  | | ||
| Human | E. coli | Human KRAS (G12A) Protein, His Tag (active enzyme) |  | | ||
| Human | E. coli | Human KRAS (G12R) Protein, His Tag (active enzyme) |  | | ||
| Human | E. coli | Human KRAS (Q61H) Protein, His Tag (active enzyme) |  | | ||
| Human | E. coli | Human KRAS (G13D) Protein, His Tag (active enzyme) |  | | ||
| Human | E. coli | Unconjugated Human KRAS (G12V) Protein, His,Avitag™ (active enzyme) |  | |
総数量13
- 1
- 2
KRASバックグランド
KRAS (Kirsten rat sarcoma 2 viral oncogene homolog) gene is a proto-oncogene that encodes a small GTPase transductor protein called KRAS. KRAS is also known as Ki-Ras, c-K-ras and c-Ki-ras. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation, promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner. RAS is one of the most frequently mutated oncogenes in human cancer but the frequency and distribution of RAS gene mutations are not uniform. In details, mutation of glycine 12 (G12) causes RAS activation by interfering with GAP binding and GAP-stimulated GTP hydrolysis. The reference shows the pathway may as a potential therapy targets.
KRAS分子の別称
GTPase Kras,K-Ras 2,Ki-Ras,c-K-ras,c-Ki-ras,KRAS2,RASK2,C-K-RAS,CFC2,K-RAS2A,K-RAS2B,K-RAS4A,K-RAS4B,KI-RAS,KRAS1,KRAS2,NS,NS3,RASK2,KRAS
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Pooled mutant-KRAS peptide vaccine (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) | Phase 2 Clinical | Sidney Kimmel Comprehensive Cancer Center | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Pancreatic Neoplasms | 詳細 | |
| KRAS Neoantigen Nanovaccine (The Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School) | Phase 2 Clinical | The Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School | Colorectal Neoplasms; Pancreatic Neoplasms | 詳細 | |
| HBW-012462 | HBW-012462 | Phase 2 Clinical | Hyperway Pharmaceutical Co Ltd | Solid tumours | 詳細 |
| JAB-23E73 | JAB-23E73 | Phase 2 Clinical | Jacobio Pharmaceuticals Group Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours | 詳細 |
| ZG-2001 | ZG2001; ZG-2001 | Phase 2 Clinical | Suzhou Zelgen Biopharmaceuticals Co Ltd | Neoplasms; Solid tumours | 詳細 |
| ELI-002 | ELI-002 2P; Amph-CpG-7909; ELI-002; VED-002 | Phase 2 Clinical | Elicio Therapeutics | Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Neoplasm, Residual; Ovarian Neoplasms; Solid tumours | 詳細 |
| mDC3/8-KRAS Vaccine (University of Pennsylvania) | Phase 1 Clinical | University Of Pennsylvania | Carcinoma, Pancreatic Ductal | 詳細 | |
| small molecule Ras inhibitors (Boehringer Ingelheim/Vanderbilt University) | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Neoplasms | 詳細 | |
| KRAS peptide vaccine (Sidney Kimmel Cancer Center/Bristol-Myers Squibb) | Phase 1 Clinical | Sidney Kimmel Comprehensive Cancer Center | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Pancreatic Neoplasms | 詳細 | |
| KrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes (Codiak BioSciences) | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms | 詳細 | |
| HB-700 | HB700; HB-700 | Phase 1 Clinical | Hookipa Pharma Inc | Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms | 詳細 |
| KST-6051 | KST-6051 | Phase 1 Clinical | Kestrel Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours | 詳細 |
| TQB-3205 | TQB-3205; TQB3205 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Neoplasms | 詳細 |
| PT-0511 | PT-0511; PT0511 | Phase 1 Clinical | PAQ Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours | 詳細 |
| TLN-372 | TLN-372 | Phase 1 Clinical | Treeline Biosciences Inc | Solid tumours | 詳細 |
| ASP-5834 | ASP5834; ASP-5834 | Phase 1 Clinical | Astellas Pharma Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours | 詳細 |
| AMG-410 | AMG-410; AMG 410 | Phase 1 Clinical | Amgen Inc | Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours | 詳細 |
| MPD-1 | MPD-1 | Phase 1 Clinical | Pharosgen Co Ltd | Neoplasms; Solid tumours | 詳細 |
| KRAS protein modulator (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | 詳細 | |
| PF-07985045 | PF-07985045; PF-5045 | Phase 1 Clinical | Pfizer Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours | 詳細 |
| LY-4066434 | LY-4066434 | Phase 1 Clinical | Loxo Oncology Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours | 詳細 |
| BGB-53038 | BGB-53038 | Phase 1 Clinical | BeOne Medicines Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastrointestinal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Solid tumours; Stomach Neoplasms | 詳細 |
| KRAS Neoantigen mRNA Vaccine(Abogen Biosciences) | ABO2102; ABO-2102 | Phase 1 Clinical | Abogen Biosciences Co Ltd | Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms; Solid tumours | 詳細 |
| PF-07934040 | PF-4040; PF-07934040 | Phase 1 Clinical | Pfizer Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours | 詳細 |
| ERAS-4001 | ERAS-4001 | Phase 1 Clinical | Erasca Inc | Solid tumours | 詳細 |
| BBO-11818 | BBO-11818 | Phase 1 Clinical | Bridgebio Pharma Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Pancreatic Neoplasms | 詳細 |
| ALTA-3263 | ALTA-3263 | Phase 1 Clinical | Alterome Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours | 詳細 |
| QTX-3544 | QTX-3544; QTX3544 | Phase 1 Clinical | Quanta Therapeutics Inc | Neoplasms; Solid tumours | 詳細 |
| AN-9025 | AN-9025; AN9025 | Phase 1 Clinical | Hangzhou Adlai Nortye Biopharma Co Ltd | Adenocarcinoma of Lung; Colorectal Neoplasms; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours | 詳細 |
| BI-3706674 | BI-3706674; BI3706674; BI 3706674 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Esophageal Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| YL-17231 | YL-17231; YL17231; TEB-17231 | Phase 1 Clinical | YL-Pharma | Neoplasms; Solid tumours | 詳細 |
| QTX-3034 | QTX3034; QTX-3034 | Phase 1 Clinical | Quanta Therapeutics Inc | Neoplasms; Solid tumours | 詳細 |
| Zoldonrasib | RMC-9805; RM-036 | Phase 1 Clinical | Revolution Medicines Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Neoplasms; Solid tumours | 詳細 |
| BEBT-607 | C200825009-FP; BEBT-607 | Phase 1 Clinical | Guangzhou BeBetter Medicine Technology Co | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | 詳細 |
| BI-1701963 | BI-1701963 | Phase 1 Clinical | Forma Therapeutics Holdings Inc | Colorectal Neoplasms; Solid tumours | 詳細 |
| Targeted KRAS TCR-T cell therapy(Immuxell Biotech) | Clinical | Shanghai Immuxell Biotech Ltd | Carcinoma, Pancreatic Ductal | 詳細 | |
| CWG-59r | CWG-59r; CWG-59-r; CWG59r | Clinical | Cellworks Group | Neoplasms | 詳細 |
| CWG-71b | CWG-71b; CWG-71-b; CWG71b | Clinical | Cellworks Group | Neoplasms | 詳細 |
| CWG-89 | CWG-89 | Clinical | Cellworks Group | Neoplasms | 詳細 |
| CWG-71a (Cellworks Group) | CWG-71a | Clinical | Cellworks Group Inc | Neoplasms | 詳細 |
- 詳細
- 製品リスト
- 治験薬に関する情報